The POLARx cryoballoon achieved 100% pulmonary vein isolation, identical to the Arctic Front Advance PRO, with similar complication rates (0% vs. 5.7%, p=0.39) but longer procedural times.
Cohort
No
Does the novel POLARx cryoballoon improve procedural efficacy and safety compared to the historical AFAP cryoballoon in patients undergoing atrial fibrillation ablation?
The novel POLARx cryoballoon demonstrated similar procedural efficacy (100% pulmonary vein isolation) and safety compared to the established AFAP platform, though it was associated with longer procedural times.
Tasa de eventos absoluta: 100% vs 100%
INTRODUCTION: Catheter ablation is superior to drugs regarding atrial fibrillation (AF) recurrence, symptoms improvement, and mortality reduction in heart failure. POLARx™ is a novel cryoballoon, with technical improvements seeking to improve outcomes. So far, its clinical evidence is restricted to a case report. METHODS: To compare the POLARx™ cryoballoon procedural safety and efficacy to the already established Arctic Front Advance PRO™ (AFAP) in a single-center cohort study, consecutive patients undergoing AF cryoablation with the POLARx™ were enrolled. Data were prospectively gathered. POLARx™ patients were compared with a historical cohort of patients submitted to AF cryoablation with the AFAP. RESULTS: -VASc 1, left-atrium size 34 ml/m², and 65% were receiving anticoagulation. The primary end-point, all pulmonary veins isolation, was 100% in both groups. The complication rate was similar (0% POLARx™ vs. 5.7% AFAP, p = .39). The median total procedural time was longer in the POLARx™ group (90 min vs. 60 min, p < .001), but the overall time-to-isolation (TTI; 44.8 s vs. 39 s, p = .253) and ablation time (15 min vs. 13.7 min, p = .122) was similar between POLARx™ and AFAP groups, respectively. Despite equal TTI, the POLARx™ had a lower minimal temperature reached (-57°C vs -47°C, p < .001). CONCLUSION: The novel POLARx™ cryoballoon had similar efficacy and safety compared with the AFAP. It was also associated with longer procedural times, similar TTI, and lower minimum temperature reached.
Kochi et al. (Sat,) conducted a cohort in Atrial fibrillation. POLARx cryoballoon vs. Arctic Front Advance PRO (AFAP) cryoballoon was evaluated on All pulmonary veins isolation. The POLARx cryoballoon achieved 100% pulmonary vein isolation, identical to the Arctic Front Advance PRO, with similar complication rates (0% vs. 5.7%, p=0.39) but longer procedural times.